Riskpilot← Back to searchSign inGet full accessMIRAPHARM Aktiebolag
ABActiveOrg 5563389401Hultgrens Väg 36Accounting, bookkeeping and auditing activities; tax consultancy · NACE 6920Est. 19880 employees
Revenue 2025
SEK 204K
+10% vs 2024
EBITDA margin
13.7%
+2900% vs 2024
Equity ratio
97.2%
Financial strength
Net profit 2025
SEK 47K
0% vs 2024
| Revenue | SEK 204K | +10% |
| EBITDA | SEK 28K | +2900% |
| Net profit | SEK 47K | +0% |
| Total assets | SEK 1,4M | -9% |
| Equity | SEK 1,4M | -10% |
| Employees | 0 | — |
Legal name
MIRAPHARM Aktiebolag
Org number
5563389401
Legal form
Aktiebolag
NACE code
6920 · Accounting, bookkeeping and auditing activities; tax consultancy
Founded
31 oktober 1988
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av suppleanterna
Company purpose
Bolaget skall bedriva handel med medicinsk-teknisk utrustning, kapitalvaror samt ekonomisk och finansiell rådgivning även idka därmed förenlig verksamhet.
Address
Hultgrens Väg 36
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 101 | 115 | 149 | 186 | 204 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 54 | 26 | −11 | −1 | 28 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 54 | 26 | −11 | −1 | 28 |
| Net financials | 2 | 4 457 | 48 | 61 | 32 |
| Profit before tax | 56 | 4 483 | 37 | 61 | 60 |
| Tax | −12 | −10 | −11 | −14 | −13 |
| Net profit | 44 | 4 473 | 26 | 47 | 47 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 250 | 4 596 | 2 054 | 1 583 | 1 436 |
| Equity | 224 | 4 577 | 2 002 | 1 549 | 1 396 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 26 | 19 | 52 | 34 | 41 |
| Total debt | 26 | 19 | 52 | 34 | 41 |
EBITDA margin
13.7%
This company
15.8%
Market median
-13% vs market
20212025
Equity ratio
97.2%
This company
38.2%
Market median
+154% vs market
20212025
Return on equity
3.4%
This company
18.4%
Market median
-82% vs market
20212025
Net profit margin
23.0%
This company
8.1%
Market median
+184% vs market
20212025
Asset turnover
0.14×
This company
1.12×
Market median
-88% vs market
20212025
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AC | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MIRAPHARM Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Cecilia Grimslätt | Audit | 0 companies |
| Erik Kristofer Radnäs | Deputy Board Member | 0 companies |
| Axel William Radnäs | Deputy Board Member | 0 companies |
| Emma Maria Radnäs Koch | Deputy Board Member | 0 companies |
| Lars Erik Radnäs | Board of Directors | 0 companies |